LAUSR

We thank Erodes et al. for their much-needed international consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery [1]. They state “patients who underwent cardiac surgery in a recent study did not experience increased bleeding events with rivaroxaban in comparison with vitamin K antagonist treatment” [1], referencingapaperby Patel et al. [2]. However, the referenced study is a double-blind trial of patients with atrial fibrillation examiningwhether rivaroxabanwasnon-inferior towarfarin for theprimary end-point of stroke or systemic embolism.Noneof the studypatients underwent cardiac surgery.Wewould like to ask the authors, therefore, whether they think that the conclusions they drew based on this study in their consensus statementmaybemisleading in the context of cardiac surgery. We would also like to seek clarification on the meaning of the abbreviation ‘Tc’ in Fig. 1, which has not been included in the key. Finally, we would like to ask the authors for clarification about their considering the administration of platelets, cryoprecipitate and prothrombin complex concentrate to be ‘N/A’when the bleeding tendency is classified as severe.